Polyclonal Antibody News and Research

RSS
Vaccine-induced neutralizing and non-neutralizing antibody activity against SARS-CoV-2

Vaccine-induced neutralizing and non-neutralizing antibody activity against SARS-CoV-2

How do BNT162b2 vaccine-induced neutralizing and non-neutralizing antibodies synergize to promote protection against SARS-CoV-2?

How do BNT162b2 vaccine-induced neutralizing and non-neutralizing antibodies synergize to promote protection against SARS-CoV-2?

Antibody evasion of Omicron BA.2.75 is less pronounced than BA.4/5

Antibody evasion of Omicron BA.2.75 is less pronounced than BA.4/5

Study tests equine polyclonal antibodies against SARS-CoV-2 variants

Study tests equine polyclonal antibodies against SARS-CoV-2 variants

Doggybone DNA COVID-19 vaccine can effectively neutralize SARS-CoV-2 variants

Doggybone DNA COVID-19 vaccine can effectively neutralize SARS-CoV-2 variants

Cost-effective ovine antibody-based therapy against SARS-CoV-2 infection

Cost-effective ovine antibody-based therapy against SARS-CoV-2 infection

Study describes ultra-structure of Nipah virus surface glycoprotein

Study describes ultra-structure of Nipah virus surface glycoprotein

Role of natural immunity to SARS-CoV-2 on post-vaccination antibody responses in staff and residents of long-term care facilities

Role of natural immunity to SARS-CoV-2 on post-vaccination antibody responses in staff and residents of long-term care facilities

SARS-CoV-2 Delta variant-induced antibody response largely focuses on class 1 and 2 antibody epitopes

SARS-CoV-2 Delta variant-induced antibody response largely focuses on class 1 and 2 antibody epitopes

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

Assessing the neutralizing ability of polyclonal antibody XAV-19 against SARS-CoV-2 Omicron variant

COVID-19 infection sera analysis against varying antigens of SARS-CoV-2 variants

COVID-19 infection sera analysis against varying antigens of SARS-CoV-2 variants

SARS-CoV-2 Omicron variant uses endosomal entry pathway and grows in upper respiratory tract cells

SARS-CoV-2 Omicron variant uses endosomal entry pathway and grows in upper respiratory tract cells

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

New tool to help map immune escape with SARS-CoV-2 mutations

New tool to help map immune escape with SARS-CoV-2 mutations

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine

Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine

Antibody validation and rapid peptide mapping technology

Antibody validation and rapid peptide mapping technology

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial